This book is intended to help decision-makers use, assess and appraise the evidence that underpins decisions about the use of therapeutic interventions. It will inform decision-makers about the nature of evidence, the strengths and weaknesses of the available approaches, and how these can be most effectively distilled for the purpose of reaching reliable conclusions. It aims to encourage decision-makers to base their judgements about the use of therapeutic interventions on an informed appraisal of the totality of the evidence base. Is it reliable? Is it generalisable beyond the context of the environment in which the primary research has been conducted? Do the intervention's benefits outweigh its harms? Is it cost effective as well as clinically effective? Is it, indeed, fit-for-purpose? Ultimately, good judgement is at the heart of decision-making in therapeutics.
An invaluable text for all physicians, pharmacists, nurses, health commissioners and purchasers and indeed anyone having to make decisions concerning evidence-based therapeutics.
By:
Michael Rawlins (National Institute for Health and Clinical Excellence London UK) Imprint: Royal Society of Medicine Press Ltd Country of Publication: United Kingdom Dimensions:
Height: 234mm,
Width: 156mm,
Spine: 13mm
Weight: 340g ISBN:9781853159473 ISBN 10: 1853159476 Pages: 256 Publication Date:29 July 2011 Audience:
Professional and scholarly
,
Undergraduate
Format:Paperback Publisher's Status: Active
Introduction: The nature of evidence. Probability. Clinical endpoints of benefits and harms. Statistical expressions of benefit and harm. Bias and confounding. Systematic reviews. Randomized controlled trials: . General principles. Stopping rules. Analysis of subgroups. Safety. Generalizability. Observational studies: General overview. Historical controlled trials. Concurrent cohort studies. Case-control designs. Databases. Case reports. Qualitative research: Approaches and methods. Uses in the evaluation of therapeutic interventions. Economic evaluation: General principles. Cost-effectiveness, cost-utility and cost-minimization analyses. Cost-consequences analysis. Decision-making: . For individuals. For populations.
"""Professor Sir Michael Rawlins MD FRCP(Lond) FRCP(Edin) FFPM FMedSci, National Institute for Clinical Excellence, London, UK """